Sodium Butyrate, HDAC3/c-Myc, and Liver Fibrosis

The reference study, Gut-Derived Sodium Butyrate Attenuates Liver Fibrosis by Inhibiting Aerobic Glycolysis via the HDAC3/c-Myc Signaling Axis, addresses how a gut microbiota-derived metabolite influences fibrotic remodeling in the liver. Published in The FASEB Journal in 2026, the work combines network-level prediction with molecular, cellular, and animal experiments to define a pathway connecting sodium butyrate, histone deacetylase 3, c-Myc, glycolysis, and hepatic stellate-cell activation. The findings are reported in the open-access reference study.

Study Background and Research Question

Liver fibrosis is a common response to chronic injury arising from viral hepatitis, alcohol exposure, and metabolic dysfunction-associated steatotic liver disease. Its defining feature is excessive extracellular-matrix deposition, which progressively alters hepatic architecture and can advance to cirrhosis, liver failure, or hepatocellular carcinoma. Despite extensive investigation of fibrogenic signaling, approved therapies that directly reverse liver fibrosis remain limited, creating a need for mechanistically grounded targets.

The gut–liver axis provides a plausible route through which microbial metabolism can affect hepatic disease. Short-chain fatty acids produced in the intestine can reach the liver through portal circulation and influence immune, metabolic, and epigenetic processes. Sodium butyrate, or NaB, is particularly relevant because it has anti-inflammatory and histone deacetylase-inhibitory properties, but the molecular basis of its anti-fibrotic activity has not been fully resolved.

The central question was therefore not simply whether NaB reduces fibrosis, but how it changes the behavior of hepatic stellate cells. The investigators focused on whether NaB suppresses a metabolic phenotype associated with stellate-cell activation and whether HDAC3 and c-Myc form a functional signaling axis in that process.

Key Innovation from the Reference Study

The principal innovation is the integration of epigenetic regulation with aerobic glycolysis in the explanation of NaB-mediated fibrosis attenuation. Rather than treating NaB as a broadly anti-inflammatory metabolite, the study positions it as an upstream regulator of HDAC3 activity. In the proposed model, reduced HDAC3 expression and deacetylase activity increase c-Myc acetylation, lower c-Myc abundance, and weaken transcriptional support for glycolytic enzymes.

This creates a mechanistic chain from a gut-derived metabolite to cellular metabolic reprogramming: NaB inhibits HDAC3, c-Myc is acetylated and downregulated, glycolytic capacity decreases, and activated hepatic stellate cells express fewer fibrotic markers. The study identifies HK2, PFKFB3, and PKM2 as key metabolic components of this response, while α-SMA and type I collagen provide readouts of the fibrogenic phenotype. The proposed pathway is summarized in the reference article, which presents HDAC3 as both a candidate molecular driver and a pharmacologically relevant point of intervention.

Methods and Experimental Design Insights

The experimental design proceeds from prediction to target validation and then to functional testing. Bioinformatics and network pharmacology were first used to identify candidate targets associated with NaB and liver fibrosis. This approach is useful for prioritizing pathway components, although it generates hypotheses rather than establishing direct molecular action.

Molecular docking was used to examine the plausibility of interactions between NaB and candidate proteins. The investigators then used cellular thermal shift assay, or CETSA, and surface plasmon resonance, or SPR, to strengthen the evidence for target engagement. CETSA can indicate whether ligand binding changes the thermal stability of a protein in a cellular context, whereas SPR measures binding interactions using an immobilized partner and provides direct biophysical evidence. Their combined use is more informative than docking alone because it tests whether a predicted interaction is experimentally detectable.

Functional validation was conducted in LX-2 hepatic stellate cells and in mice with carbon tetrachloride-induced liver injury and fibrosis. In vitro experiments examined whether NaB altered HDAC3, c-Myc, glycolytic enzymes, and fibrotic markers in a stellate-cell model. In vivo experiments assessed whether the same molecular pattern accompanied reduced hepatic injury and fibrosis. The study used Western blotting, immunofluorescence, co-immunoprecipitation, reverse-transcription quantitative PCR, ELISA, and histopathological staining, as described in the published methods and results.

Protocol Parameters

• Cellular model: LX-2 hepatic stellate cells were used to test NaB-associated changes in signaling, glycolysis, and fibrotic activation. Replication should preserve the reported cell culture conditions and treatment schedule from the full article.
• Animal model: Carbon tetrachloride-induced mice provided an in vivo model of hepatic injury and fibrosis. The model is appropriate for testing whether molecular changes observed in LX-2 cells are accompanied by tissue-level improvement.
• Target engagement: Molecular docking, CETSA, and SPR should be interpreted as complementary evidence. Docking is predictive, CETSA addresses cellular protein stabilization, and SPR supplies biophysical interaction data.
• Mechanism-focused readouts: HDAC3 and c-Myc should be assessed alongside HK2, PFKFB3, and PKM2 so that changes in signaling can be related to glycolytic reprogramming rather than measured in isolation.
• Fibrosis assessment: α-SMA, type I collagen, biochemical injury measures, and histopathological findings provide distinct levels of evidence. A convincing replication should evaluate molecular, cellular, and tissue endpoints together.
• Suggested workflow discipline: The supplied study summary does not establish a universal NaB dose or treatment schedule. Researchers should use the full paper for exact experimental parameters and avoid treating a single model-specific regimen as a general therapeutic standard.

Core Findings and Why They Matter

HDAC3 emerged as a central fibrosis-associated target in the computational analysis and subsequent validation. In both fibrotic liver tissue and LX-2 cells, NaB was associated with lower HDAC3 expression and reduced deacetylase activity. These observations support the interpretation that HDAC3 is not merely correlated with fibrosis in this system but participates in the molecular response to NaB.

The next important finding involved c-Myc. NaB promoted c-Myc acetylation while reducing c-Myc expression. Because c-Myc can coordinate expression of genes supporting cell growth and glycolytic metabolism, its downregulation offers a plausible explanation for the concurrent decrease in HK2, PFKFB3, and PKM2. The results therefore connect an epigenetic modification state with a metabolic phenotype in hepatic stellate cells.

At the tissue and cellular levels, these molecular changes were accompanied by lower α-SMA and type I collagen, together with attenuation of CCl4-induced hepatic injury and fibrosis. The significance is conceptual as well as therapeutic: the study suggests that activated stellate cells may be controlled partly by interrupting their metabolic support system. This expands the anti-fibrotic framework beyond cytokine signaling and matrix turnover to include glycolytic regulation.

The results do not establish that NaB is an approved treatment or that HDAC3/c-Myc is the only relevant pathway. They do, however, provide a coherent multi-level explanation supported by target prediction, binding-related assays, cell experiments, and an animal model. That layered evidence is the study’s strongest contribution.

Comparison with Existing Internal Articles

The available internal resources approach the subject from a different direction. An internal protocol and QC guide concentrates on practical detection of mouse-derived primary antibodies in Western blot, ELISA, immunohistochemistry, and immunocytochemistry. Its value is operational: it helps researchers think about assay compatibility, controls, and reagent handling, whereas the reference study is concerned with establishing a biological mechanism.

A separate mechanism-focused internal resource discusses how enzyme-linked secondary detection can support signal amplification. That topic is relevant to measuring HDAC3, c-Myc, glycolytic enzymes, or fibrosis markers, but it should not be confused with evidence that any detection reagent causes the observed biological effects. Together, the internal articles complement the paper at the assay implementation level without replacing the study’s biochemical and in vivo validation.

Limitations and Transferability

Several limitations affect how broadly the findings should be interpreted. First, the mechanistic evidence is anchored in LX-2 cells and a CCl4-induced mouse model. These systems are valuable for controlled experimentation, but they do not reproduce the full heterogeneity of human fibrosis caused by viral infection, alcohol exposure, or metabolic liver disease. Human stellate-cell populations, primary hepatocytes, immune cells, and gut microbial communities may respond differently.

Second, network pharmacology and molecular docking can prioritize HDAC3 but cannot by themselves prove selectivity. NaB is a pleiotropic metabolite with effects that may involve other histone deacetylases, metabolite-sensing pathways, intestinal barrier biology, and inflammatory signaling. The CETSA and SPR results improve the case for HDAC3 engagement, yet additional genetic loss-of-function, rescue, and selectivity experiments would help determine how necessary the HDAC3/c-Myc axis is relative to parallel mechanisms.

Third, reduced glycolytic enzyme expression does not automatically demonstrate a complete change in metabolic flux. Direct measurements of glucose uptake, lactate production, oxygen consumption, extracellular acidification, and isotope tracing could clarify whether the observed protein changes represent functional suppression of aerobic glycolysis. Finally, the study provides preclinical mechanistic evidence rather than clinical efficacy, pharmacokinetic, or dosing evidence. Transfer to human therapy will require validation in additional models and carefully designed clinical research.

Research Support Resources

Why this cross-domain matters, maturity, and limitations

Connecting a liver-fibrosis mechanism to immunodetection tools is a practical assay bridge, not additional proof of the NaB pathway. Reliable detection can help researchers reproduce protein-level observations, but antibody performance depends on primary-antibody species, tissue preparation, blocking conditions, controls, and assay optimization. These considerations are especially important when comparing Western blot, ELISA, immunofluorescence, and tissue-based measurements.

For workflows that use mouse primary antibodies, researchers can use the HRP Goat Anti-Mouse IgG (H+L) Antibody (SKU K1221), an Affinity-Purified Goat Anti-Mouse IgG (H+L), HRP Conjugated reagent. This Horseradish Peroxidase conjugated secondary antibody is relevant as a secondary antibody for Western blot detection, a secondary antibody for ELISA assays, and an immunohistochemistry secondary antibody; enzymatic labeling can support signal amplification in immunoassays. The linked product information should be consulted for formulation, storage, and application-specific handling. It supports detection workflows analogous to those used to quantify pathway and fibrosis markers, but it does not substitute for the reference study’s mechanistic controls.